Collaboration will support a secure, compliant and unified platform to improve customer experience and patient outcomes
Combined expertise from both companies poised to make a significant impact in MedTech
NEW BRUNSWICK, N.J. (January 10, 2022) The Johnson & Johnson Medical Devices Companies (JJMDC)* today announced that it will collaborate with Microsoft to further enable and expand JJMDC’s secure and compliant digital surgery ecosystem. The Microsoft Cloud will help JJMDC realize its vision of driving innovation that advances skills, improves workflow, and enhances surgical decision making for a better overall customer experience and improved patient and economic outcomes.
JJMDC’s innovative medical technology exists across an ecosystem that includes next generation robotics, world-class instrumentation, advanced imaging and visualization, data and analytics, artificial intelligence, machine learning, and digital solutions. To mobilize the potential of these assets and make a clinical difference for patients, it is imperative to establish robust connectivity with, and between, all elements of the ecosystem with a seamless, interconnected network that meets surgeons where they are in their workflow and patients where they are in their healthcare journey.
“Collaborating with Microsoft will help take our digital approach to the next level as we create a best-in-class, unified platform across our innovative surgical technologies,” said Larry Jones, Group CIO and Global Vice President, Medical Devices, Johnson & Johnson. “It brings together our collective expertise and is an exciting step towards creating a connected patient journey across the entire care continuum, before, during, and after a procedure.”
As part of the strategic partnership, Microsoft will serve as JJMDC’s preferred cloud provider for the company’s digital surgery solutions and help JJMDC build out its digital surgery platform and internet of things (IoT) device connectivity. By harnessing the power of the Microsoft Cloud, including Azure, artificial intelligence (AI), and machine learning, Microsoft 365 and Dynamics 365, the companies expect to work together to deliver innovation across the following areas:
· Innovating to improve patient outcomes through artificial intelligence, machine learning and data insights.
· Increasing JJMDC device connectivity, insights and intelligence using Azure IoT and Edge Computing technologies.
· Increasing the pace of digital innovation and transformation across the JJMDC digital surgery ecosystem using Azure capabilities and services.
“At the Johnson & Johnson Medical Devices companies, we’re shaping a future where medical intervention is smarter, less invasive, and more personalized,” said Peter Schulam, MD, PhD, Global Head, Medical Affairs, Clinical Affairs and Pre-Clinical Research, Johnson & Johnson Medical Devices Companies, and Leader, Office of Digital Innovation. “We’re excited to collaborate with Microsoft on this important work as we continue to expand our digital surgery assets and capabilities, develop innovative and advanced instrumentation, and make a meaningful clinical difference for customers and patients.”
About Johnson & Johnson Medical Devices Companies:
At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the Johnson & Johnson Medical Devices Companies digital surgery ecosystem. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Medical Device Business Services, Inc., the Johnson & Johnson Medical Device Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to:; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Medical Device Business Services, Inc., the Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
*The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s Medical Devices segment. The legal entity named in this agreement is Medical Device Business Services, Inc.